<DOC>
	<DOCNO>NCT03041285</DOCNO>
	<brief_summary>The aim study determine toxicity Idronoxil ( NOX66 ) use combination palliative radiotherapy metastatic prostate cancer</brief_summary>
	<brief_title>Idronoxil Suppository Combine With Radiotherapy Metastatic Prostate Cancer</brief_title>
	<detailed_description>Who ? Patient may eligible study late stage metastatic prostate cancer castrate resistant metastatic lesion suitable radiotherapy . Study detail There two group patient study randomisation . The two group two different dos idronoxil ( NOX66 ) , represent 2-step dose escalation . Both group receive standard radiotherapy dose . Group 1 receive low dose ( 400 mg ) idronoxil suppository daily Group 2 800 mg daily . Recruitment Group 2 commence Group 1 patient complete 13-day treatment course idronoxil suppository without excessive unexpected toxicity . The total treatment duration 26 day group . WEEK 1 : Days 1-5 : 1 2 lesion receive 20-25 Gy ( radiotherapy dose unit ) radiotherapy 5 daily fractionate dos . WEEK 2 : Rest week . No radiotherapy . Start NOX66 Day 14 WEEK 3 : DAYS 15-19 : NOX66 therapy . DAYS 15-19 : Remaining lesion ( maximum 3 lesion ) receive 20-25 Gy RT 5 daily fractionate dos . WEEK 4 : DAYS 20-26 : NOX66 therapy . Both group prostate-specific membrane antigen positron emission tomography ( PSMA-PET ) scan start treatment three month last fraction radiotherapy ass treatment response .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Confirmed metastatic prostate cancer castrateresistant . 23 lesion suitable radiotherapy . ECOG Performance status 02 . Adequate bone marrow , hepatic renal function At least 4 week must elapse prior commencement idronoxil treatment since prior chemotherapy , investigational drug biologic therapy Chemotherapy regimens delay toxicity within last 4 week . Any situation use suppository therapy contraindicate impractical ( eg . chronic diarrhoea , colostomy , ulcerative colitis ) . No concurrent systemic chemotherapy biologic therapy allow . Psychiatric disorder social geographic situation would preclude study participation . Patient unable provide consent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>